Diapositive 1

Phase II trial (NCT02314169)

• Inclusion: previously-treated metastatic patients

• Primary Endpoint: Tumor response (RECIST 1.1)

Results:

• Response in 9 of 37 patients (24%; CR in n=2)

• Median OS: 11.5 months; median PFS: 4.1

months

• Good toxicity profile, no SAEs

Nivolumab for previously treated

unresectable metastatic anal cancer

Higher immunogenicity Better

response

Morris et al, Lancet Oncolology 20